Development and maintenance of cancer stem cells under chronic inflammation

Journal of Nippon Medical School

Volumn 78, Issue 3, 2011, Pages 138-145

  Tanno, Toshihiko ^a   Matsui, William ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cell; Chronic inflammation

Indexed keywords

CELL PROTEIN; CYCLIN D1; FORKHEAD TRANSCRIPTION FACTOR; GLYCOPROTEIN GP 130; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANEMIA; APOPTOSIS; BARRETT ESOPHAGUS; BURKITT LYMPHOMA; CANCER GROWTH; CANCER RISK; CANCER STEM CELL; CARCINOGENESIS; CELL ACTIVITY; CELL DAMAGE; CELL DIFFERENTIATION; CELL IMMORTALIZATION; CELL MATURATION; CELL PROLIFERATION; CELL RENEWAL; CELL SURVIVAL; CELL TRANSFORMATION; CHRONIC INFLAMMATION; COLON ADENOCARCINOMA; CYTOKINE RELEASE; DISEASE ASSOCIATION; DNA DAMAGE; ENTERITIS; EPITHELIAL MESENCHYMAL TRANSITION; EPSTEIN BARR VIRUS; ESOPHAGUS CARCINOMA; GASTROESOPHAGEAL REFLUX; GENE INACTIVATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTOXICITY; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; HYPOXIA; LEUKOPENIA; LIVER CELL CARCINOMA; METAPLASIA; MULTIPLE MYELOMA; NASOPHARYNX CARCINOMA; NEURAL STEM CELL; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATIVE STRESS; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CARCINOMA; T CELL DEPLETION; TISSUE INJURY; TISSUE REGENERATION; TISSUE REPAIR; TUMOR MICROENVIRONMENT; ULCERATIVE COLITIS; UTERINE CERVIX CARCINOMA; VIRUS GENE;

CHRONIC DISEASE; HUMANS; INFLAMMATION; NEOPLASTIC STEM CELLS; OXIDATIVE STRESS; REGENERATION; WOUND HEALING;

EID: 79959647616     PISSN: 13454676     EISSN: 13473409     Source Type: Journal    
DOI: 10.1272/jnms.78.138     Document Type: Review

References (83)

1. Lobo NA, Shimono Y, Qian D, Clarke MF: The biology of cancer stem cells. Annu Rev Cell Dev Biol 2007; 23: 675-699.
2. Lapidot T, Sirard C, Vormoor J, et al.: A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994; 367: 645-648.
3. Zucchi I, Sanzone S, Astigiano S, et al.: The properties of a mammary gland cancer stem cell. Proc Natl Acad Sci U S A 2007; 104: 10476-10481.
4. Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004; 432: 396-401.
5. Dalerba P, Dylla SJ, Park IK, et al.: Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007; 104: 10158-10163.
6. O'Brien CA, Pollett A, Gallinger S, Dick JE: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007; 445: 106-110.
7. Dalerba P, Cho RW, Clarke MF: Cancer stem cells: models and concepts. Annu Rev Med 2007; 58: 267-284.
8. Jones RJ, Matsui WH, Smith BD: Cancer stem cells: are we missing the target? J Natl Cancer Inst 2004; 96: 583-585.
9. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-545.
10. Hussain SP, Harris CC: Inflammation and cancer: an ancient link with novel potentials. Int J Cancer 2007; 121: 2373-2380.
11. Moody CA, Laimins LA: Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer 2010; 10: 550-560.
12. Kutok JL, Wang F: Spectrum of Epstein-Barr virusassociated diseases. Annu Rev Pathol 2006; 1: 375-404.
13. Ferraccioli G, Tolusso B: Infections, B cell receptor activation and autoimmunity: different check-point impairments lead to autoimmunity, clonal B cell expansion and fibrosis in different immunological settings. Autoimmun Rev 2007; 7: 109-113.
14. Engels EA: Infectious agents as causes of non- Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev 2007; 16: 401-404.
15. Ekbom A, Helmick C, Zack M, Adami HO: Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet 1990; 336: 357-359.
16. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN: Ulcerative colitis and Crohn's disease: a comparison of the colorectal cancer risk in extensive colitis. Gut 1994; 35: 1590-1592.
17. Solaymani-Dodaran M, Logan RF, West J, Card T, Coupland C: Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux. Gut 2004; 53: 1070-1074.
18. Vallabhapurapu S, Karin M: Regulation and function of NF-kappaB transcription factors in the immune system. Annu Rev Immunol 2009; 27: 693-733.
19. Davies FE, Rollinson SJ, Rawstron AC, et al.: Highproducer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 2000; 18: 2843-2851.
20. Machado JC, Figueiredo C, Canedo P, et al.: A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-371.
21. Shoji Y, Uedono Y, Ishikura H, Takeyama N, Tanaka T: DNA damage induced by tumour necrosis factoralpha in L929 cells is mediated by mitochondrial oxygen radical formation. Immunology 1995; 84: 543-548.
22. Aggarwal BB, Shishodia S, Sandur SK, Pandey MK, Sethi G: Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006; 72: 1605-1621.
23. He G, Karin M: NF-kappaB and STAT3-key players in liver inflammation and cancer. Cell Res 2011; 21: 159-168.
24. Hellwig-Burgel T, Rutkowski K, Metzen E, Fandrey J, Jelkmann W: Interleukin-1beta and tumor necrosis factor-alpha stimulate DNA binding of hypoxiainducible factor-1. Blood 1999; 94: 1561-1567.
25. Bierie B, Moses HL: Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev 2010; 21: 49-59.
26. Trachootham D, Lu W, Ogasawara MA, Nilsa RD, Huang P: Redox regulation of cell survival. Antioxid Redox Signal 2008; 10: 1343-1374.
27. Giles GI: The redox regulation of thiol dependent signaling pathways in cancer. Curr Pharm Des 2006; 12: 4427-4443.
28. Tothova Z, Kollipara R, Huntly BJ, et al.: FoxOs are critical mediators of hematopoietic stem cell resistance to physiologic oxidative stress. Cell 2007; 128: 325-339.
29. Naka K, Muraguchi T, Hoshii T, Hirao A: Regulation of reactive oxygen species and genomic stability in hematopoietic stem cells. Antioxid Redox Signal 2008; 10: 1883-1894.
30. Essers MA, Weijzen S, de Vries-Smits AM, et al.: FOXO transcription factor activation by oxidative stress mediated by the small GTPase Ral and JNK. EMBO J 2004; 23: 4802-4812.
31. Burgering BM: A brief introduction to FOXOlogy. Oncogene 2008; 27: 2258-2262.
32. Gomes AR, Brosens JJ, Lam EW: Resist or die: FOXO transcription factors determine the cellular response to chemotherapy. Cell Cycle 2008; 7: 3133-3136.
33. Ho KK, Myatt SS, Lam EW: Many forks in the path: cycling with FoxO. Oncogene 2008; 27: 2300-2311.
34. Myatt SS, Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 2007; 7: 847-859.
35. Fuchs D, Hausen A, Reibnegger G, et al.: Immune activation and the anaemia associated with chronic inflammatory disorders. Eur J Haematol 1991; 46: 65-70.
36. Ganz T, Nemeth E: Iron sequestration and anemia of inflammation. Semin Hematol 2009; 46: 387-393.
37. Edgren G, Bagnardi V, Bellocco R, et al.: Pattern of declining hemoglobin concentration before cancer diagnosis. Int J Cancer 2010; 127: 1429-1436.
38. Beachy PA, Karhadkar SS, Berman DM: Tissue repair and stem cell renewal in carcinogenesis. Nature 2004; 432: 324-331.
39. Widera D, Mikenberg I, Elvers M, Kaltschmidt C, Kaltschmidt B: Tumor necrosis factor alpha triggers proliferation of adult neural stem cells via IKK/NF kappaB signaling. BMC Neurosci 2006; 7: 64.
40. Audet J, Miller CL, Rose-John S, Piret JM, Eaves CJ: Distinct role of gp130 activation in promoting selfrenewal divisions by mitogenically stimulated murine hematopoietic stem cells. Proc Natl Acad Sci U S A 2001; 98: 1757-1762.
41. Jang YY, Sharkis SJ: A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood 2007; 110: 3056-3063.
42. Ito K, Hirao A, Arai F, et al.: Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells. Nature 2004; 431: 997-1002.
43. Tothova Z, Gilliland DG: FoxO transcription factors and stem cell homeostasis: insights from the hematopoietic system. Cell Stem Cell 2007; 1: 140-152.
44. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE, Chumakov PM: The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-1313.
45. Ito K, Hirao A, Arai F, et al.: Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells. Nat Med 2006; 12: 446-451.
46. Yalcin S, Zhang X, Luciano JP, et al.: Foxo3 is essential for the regulation of ataxia telangiectasia mutated and oxidative stress-mediated homeostasis of hematopoietic stem cells. J Biol Chem 2008; 283: 25692-25705.
47. Barzilai A, Rotman G, Shiloh Y: ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002; 1: 3-25.
48. Barlow C, Hirotsune S, Paylor R, et al.: Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 1996; 86: 159-171.
49. Miyamoto K, Araki KY, Naka K, et al.: Foxo3a is essential for maintenance of the hematopoietic stem cell pool. Cell Stem Cell 2007; 1: 101-112.
50. Renault VM, Rafalski VA, Morgan AA, et al.: FoxO3 regulates neural stem cell homeostasis. Cell Stem Cell 2009; 5: 527-539.
51. Gilbertson RJ, Rich JN: Making a tumour's bed: glioblastoma stem cells and the vascular niche. Nat Rev Cancer 2007; 7: 733-736.
52. Adelman DM, Maltepe E, Simon MC: Multilineage embryonic hematopoiesis requires hypoxic ARNT activity. Genes Dev 1999; 13: 2478-2483.
53. Adelman DM, Maltepe E, Simon MC: HIF-1 is essential for multilineage hematopoiesis in the embryo. Adv Exp Med Biol 2000; 475: 275-284.
54. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD: Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc Natl Acad Sci U S A 2007; 104: 5431-5436.
55. Eliasson P, Jonsson JI: The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 2010; 222: 17-22.
56. Bakker WJ, Harris IS, Mak TW: FOXO3a is activated in response to hypoxic stress and inhibits HIF1-induced apoptosis via regulation of CITED2. Mol Cell 2007; 28: 941-953.
57. Jiang J, Hui CC: Hedgehog signaling in development and cancer. Dev Cell 2008; 15: 801-812.
58. Naka K, Hoshii T, Muraguchi T, et al.: TGF-beta- FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature 2010; 463: 676-680.
59. Pervaiz S, Clement MV: Tumor intracellular redox status and drug resistance-serendipity or a causal relationship? Curr Pharm Des 2004; 10: 1969-1977.
60. Tiligada E: Chemotherapy: induction of stress responses. Endocr Relat Cancer 2006; 13 Suppl 1: S115-124.
61. Sullivan R, Graham CH: Chemosensitization of cancer by nitric oxide. Curr Pharm Des 2008; 14: 1113-1123.
62. Inda MM, Bonavia R, Mukasa A, et al.: Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev 2010; 24: 1731-1745.
63. Nilsson CL, Dillon R, Devakumar A, et al.: Quantitative phosphoproteomic analysis of the STAT3/IL-6/HIF1alpha signaling network: an initial study in GSC11 glioblastoma stem cells. J Proteome Res 2010; 9: 430-443.
64. Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002; 2: 442-454.
65. Gavert N, Ben-Ze'ev A: Epithelial-mesenchymal transition and the invasive potential of tumors. Trends Mol Med 2008; 14: 199-209.
66. Peinado H, Olmeda D, Cano A: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype? Nat Rev Cancer 2007; 7: 415-428.
67. Mani SA, Guo W, Liao MJ, et al.: The epithelialmesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
68. Vesuna F, Lisok A, Kimble B, Raman V: Twist modulates breast cancer stem cells by transcriptional regulation of CD24 expression. Neoplasia 2009; 11: 1318-1328.
69. Radisky DC, Levy DD, Littlepage LE, et al.: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005; 436: 123-127.
70. Przybylo JA, Radisky DC: Matrix metalloproteinaseinduced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int J Biochem Cell Biol 2007; 39: 1082-1088.
71. Mohyeldin A, Garzon-Muvdi T, Quinones-Hinojosa A: Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 2010; 7: 150-161.
72. Li Z, Bao S, Wu Q, et al.: Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 2009; 15: 501-513.
73. Jogi A, Ora I, Nilsson H, et al.: Hypoxia alters gene expression in human neuroblastoma cells toward an immature and neural crest-like phenotype. Proc Natl Acad Sci U S A 2002; 99: 7021-7026.
74. Mortensen BT, Jensen PO, Helledie N, et al.: Changing bone marrow micro-environment during development of acute myeloid leukaemia in rats. Br J Haematol 1998; 102: 458-464.
75. Jensen PO, Mortensen BT, Hodgkiss RJ, et al.: Increased cellular hypoxia and reduced proliferation of both normal and leukaemic cells during progression of acute myeloid leukaemia in rats. Cell Prolif 2000; 33: 381-395.
76. Wellmann S, Guschmann M, Griethe W, et al.: Activation of the HIF pathway in childhood ALL, prognostic implications of VEGF. Leukemia 2004; 18: 926-933.
77. Gross S, Cairns RA, Minden MD, et al.: Cancerassociated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 2010; 207: 339-344.
78. Ward PS, Patel J, Wise DR, et al.: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2- hydroxyglutarate. Cancer Cell 2010; 17: 225-234.
79. Green A, Beer P: Somatic mutations of IDH1 and IDH 2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 2010; 362: 369-370.
80. Abdel-Wahab O, Manshouri T, Patel J, et al.: Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias. Cancer Res 2010; 70: 447-452.
81. Yang MH, Wu MZ, Chiou SH, et al.: Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nat Cell Biol 2008; 10: 295-305.
82. Nguyen QD, De Wever O, Bruyneel E, et al.: Commutators of PAR-1 signaling in cancer cell invasion reveal an essential role of the Rho-Rho kinase axis and tumor microenvironment. Oncogene 2005; 24: 8240-8251.
83. Merchant AA, Matsui W: Targeting Hedgehog-a cancer stem cell pathway. Clin Cancer Res 2010; 16: 3130-3140.